Vaccinex Announces Early Stage SIGNAL-AD Trial Results For Pepinemab Antibody In Alzheimer's Disease; Findings Show Novel Mechanism Targeting Astrocyte Activation Delays Disease Progression
Portfolio Pulse from Benzinga Newsdesk
Vaccinex announced early-stage SIGNAL-AD trial results for its Pepinemab antibody in Alzheimer's disease, showing a novel mechanism targeting astrocyte activation that delays disease progression. These findings echo results from a Phase 2 Huntington's disease study and were presented at the Alzheimer's Association International Conference by Dr. Eric Siemers.
July 31, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaccinex's early-stage SIGNAL-AD trial results for Pepinemab show a novel mechanism targeting astrocyte activation that delays Alzheimer's disease progression. This positive development could boost investor confidence and potentially increase the stock price.
The positive early-stage trial results for Pepinemab in Alzheimer's disease, presented at a major conference, suggest a novel and effective mechanism that could attract investor interest and potentially drive up the stock price of Vaccinex.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100